RAPSODI

The RAPSODI study is a multi-center, placebo-controlled, clinical trial assessing the effectiveness of an investigational drug in delaying the onset of Type 2 diabetes in people with pre-diabetes. Pre-diabetes is a condition marked by glucose levels that are above normal but not yet reaching the diabetic range. People with pre-diabetes are at increased risk for developing diabetes and other cardiovascular related health issues. It is estimated that 16 million people in the US are pre-diabetic, in addition to the more than 18 million people living with diabetes.

The Cooper Institute has enrolled 75 participants and across the US, approximately 2100 patients are participating in RAPSODI. The study started in May 2006 and will last for three years.

During the study, patients are monitored on a monthly basis through in-person visits and phone calls. Every six months, patients complete an oral glucose tolerance test, which measures their fasting glucose levels along with their glucose levels 2 hours after drinking a glucose solution. In addition to monitoring blood sugars and other labs, patients complete physicals and other assessments to ensure their safety while participating in the study. The study staff also provide diet and exercise counseling to promote healthy behavior and lifestyle change.

Enrollment is completed and participants are now in their second year of study follow up.